Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Large Granular Lymphocytic | 3 | 2013 | 18 | 1.340 |
Why?
|
Carcinoma, Pancreatic Ductal | 6 | 2022 | 1634 | 1.300 |
Why?
|
Pancreatic Neoplasms | 8 | 2022 | 5256 | 0.930 |
Why?
|
Leucovorin | 2 | 2021 | 628 | 0.860 |
Why?
|
Fluorouracil | 2 | 2021 | 1619 | 0.690 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 105 | 0.610 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 250 | 0.580 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 340 | 0.570 |
Why?
|
Liver Neoplasms | 3 | 2021 | 4253 | 0.570 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2015 | 180 | 0.490 |
Why?
|
Peritoneal Neoplasms | 1 | 2020 | 665 | 0.480 |
Why?
|
Fever | 1 | 2020 | 1616 | 0.440 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1179 | 0.420 |
Why?
|
Cellulitis | 1 | 2014 | 206 | 0.420 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2012 | 61 | 0.420 |
Why?
|
Peptides | 2 | 2021 | 4409 | 0.410 |
Why?
|
Immunotherapy | 3 | 2022 | 4445 | 0.410 |
Why?
|
Superior Vena Cava Syndrome | 1 | 2012 | 53 | 0.400 |
Why?
|
Adrenal Gland Diseases | 1 | 2012 | 138 | 0.390 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11524 | 0.390 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13695 | 0.390 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.370 |
Why?
|
Vascular Neoplasms | 1 | 2012 | 175 | 0.360 |
Why?
|
Deoxycytidine | 1 | 2014 | 826 | 0.360 |
Why?
|
Hematologic Diseases | 1 | 2013 | 498 | 0.350 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 693 | 0.330 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2021 | 2214 | 0.330 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2014 | 1052 | 0.320 |
Why?
|
Adenocarcinoma | 3 | 2016 | 6364 | 0.320 |
Why?
|
Catheter Ablation | 1 | 2021 | 2758 | 0.310 |
Why?
|
Autoimmune Diseases | 3 | 2015 | 2133 | 0.310 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1333 | 0.280 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13102 | 0.280 |
Why?
|
Autoimmunity | 1 | 2014 | 1349 | 0.280 |
Why?
|
Esophageal Neoplasms | 1 | 2016 | 1583 | 0.270 |
Why?
|
Immunoconjugates | 2 | 2024 | 901 | 0.250 |
Why?
|
Hemorrhage | 2 | 2013 | 3461 | 0.230 |
Why?
|
Hodgkin Disease | 1 | 2011 | 1415 | 0.230 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1832 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5535 | 0.200 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 1596 | 0.180 |
Why?
|
Amphetamine-Related Disorders | 1 | 2020 | 67 | 0.180 |
Why?
|
Colonic Neoplasms | 1 | 2012 | 2541 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 3255 | 0.170 |
Why?
|
Niacinamide | 1 | 2021 | 417 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3557 | 0.170 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2018 | 58 | 0.160 |
Why?
|
Pregnancy Complications | 1 | 2012 | 2861 | 0.160 |
Why?
|
Organoids | 2 | 2022 | 701 | 0.160 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 528 | 0.160 |
Why?
|
Liposomes | 1 | 2021 | 759 | 0.150 |
Why?
|
Valproic Acid | 1 | 2020 | 445 | 0.150 |
Why?
|
Humans | 34 | 2024 | 744343 | 0.140 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 4262 | 0.140 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 990 | 0.130 |
Why?
|
Receptors, CXCR4 | 1 | 2020 | 726 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 648 | 0.130 |
Why?
|
Red-Cell Aplasia, Pure | 1 | 2014 | 30 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1038 | 0.120 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2014 | 54 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5172 | 0.120 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 2038 | 0.110 |
Why?
|
Pyoderma Gangrenosum | 1 | 2014 | 76 | 0.110 |
Why?
|
Bile Ducts | 1 | 2014 | 284 | 0.110 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2014 | 305 | 0.110 |
Why?
|
Pancytopenia | 1 | 2014 | 104 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 934 | 0.110 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3586 | 0.110 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 316 | 0.110 |
Why?
|
Aged, 80 and over | 7 | 2021 | 57776 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2014 | 4851 | 0.110 |
Why?
|
Lymphatic Metastasis | 1 | 2020 | 2924 | 0.100 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 343 | 0.100 |
Why?
|
Vena Cava, Superior | 1 | 2012 | 193 | 0.100 |
Why?
|
Treatment Outcome | 4 | 2021 | 63114 | 0.090 |
Why?
|
Immunosuppressive Agents | 2 | 2013 | 4149 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2183 | 0.090 |
Why?
|
Nanoparticles | 1 | 2021 | 1905 | 0.090 |
Why?
|
Blood Platelets | 1 | 2020 | 2508 | 0.090 |
Why?
|
Vasculitis | 1 | 2013 | 519 | 0.090 |
Why?
|
Thalidomide | 1 | 2014 | 890 | 0.080 |
Why?
|
Hepatitis B | 1 | 2014 | 695 | 0.080 |
Why?
|
Interferon-alpha | 1 | 2013 | 895 | 0.080 |
Why?
|
Prevalence | 3 | 2015 | 15226 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8428 | 0.080 |
Why?
|
Lymph Nodes | 1 | 2020 | 3474 | 0.080 |
Why?
|
Boronic Acids | 1 | 2012 | 965 | 0.080 |
Why?
|
Rheumatic Diseases | 1 | 2014 | 592 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1671 | 0.080 |
Why?
|
Male | 13 | 2021 | 350118 | 0.080 |
Why?
|
Aged | 7 | 2021 | 163280 | 0.070 |
Why?
|
Sodium | 1 | 2012 | 1623 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 2988 | 0.070 |
Why?
|
Methotrexate | 1 | 2013 | 1727 | 0.070 |
Why?
|
Pyrazines | 1 | 2012 | 1230 | 0.070 |
Why?
|
Interleukin-2 | 1 | 2013 | 1904 | 0.070 |
Why?
|
Survival Rate | 1 | 2020 | 12788 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1821 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1023 | 0.070 |
Why?
|
Multiple Myeloma | 2 | 2014 | 5181 | 0.070 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 3658 | 0.060 |
Why?
|
Prospective Studies | 5 | 2022 | 53288 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18029 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1622 | 0.060 |
Why?
|
Animals | 6 | 2020 | 168757 | 0.060 |
Why?
|
Lung Diseases | 1 | 2013 | 1886 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2014 | 2149 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2020 | 7880 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6314 | 0.050 |
Why?
|
Recurrence | 1 | 2014 | 8340 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2024 | 892 | 0.050 |
Why?
|
Middle Aged | 6 | 2021 | 213383 | 0.050 |
Why?
|
Female | 7 | 2021 | 380194 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 3712 | 0.050 |
Why?
|
Heart Transplantation | 1 | 2013 | 3110 | 0.050 |
Why?
|
Adult | 3 | 2021 | 214055 | 0.050 |
Why?
|
Mice | 4 | 2020 | 81183 | 0.040 |
Why?
|
Neoplasms | 2 | 2020 | 21683 | 0.040 |
Why?
|
Biopsy | 1 | 2012 | 6756 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 7913 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 339 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7322 | 0.040 |
Why?
|
Signal Transduction | 2 | 2018 | 23403 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2013 | 3143 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7181 | 0.040 |
Why?
|
Enoxaparin | 1 | 2020 | 377 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2012 | 11031 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2021 | 77449 | 0.040 |
Why?
|
Prognosis | 2 | 2020 | 29063 | 0.030 |
Why?
|
Endopeptidases | 1 | 2020 | 772 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 541 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1878 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2716 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2020 | 10481 | 0.030 |
Why?
|
Apoptosis | 2 | 2020 | 9727 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3689 | 0.030 |
Why?
|
Polysaccharides | 1 | 2020 | 1053 | 0.030 |
Why?
|
Mutation | 1 | 2018 | 29786 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2014 | 403 | 0.030 |
Why?
|
Taiwan | 1 | 2014 | 496 | 0.030 |
Why?
|
Seroepidemiologic Studies | 1 | 2014 | 401 | 0.030 |
Why?
|
Knee | 1 | 2014 | 274 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16689 | 0.030 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1107 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 29144 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2013 | 11124 | 0.020 |
Why?
|
Tacrolimus | 1 | 2013 | 743 | 0.020 |
Why?
|
Cell Survival | 1 | 2020 | 5882 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1850 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2016 | 1035 | 0.020 |
Why?
|
China | 1 | 2014 | 2248 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 10900 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2014 | 1782 | 0.020 |
Why?
|
Amyloidosis | 1 | 2012 | 795 | 0.020 |
Why?
|
Anticoagulants | 1 | 2020 | 4599 | 0.020 |
Why?
|
Myocarditis | 1 | 2012 | 771 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2013 | 1339 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9687 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9849 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13408 | 0.010 |
Why?
|
Skin | 1 | 2014 | 4364 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10388 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 21746 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 72290 | 0.010 |
Why?
|
Concepts
(166)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(27)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_